Russian Journal of BiotherapyRussian Journal of BiotherapyРоссийский биотерапевтический журнал1726-97841726-9792Publishing House ABV Press112110.17650/1726-9784-2018-17-4-20-26REVIEWSОБЗОРЫ ЛИТЕРАТУРЫIndolocarbazole derivatives – a promising class of anticancer drugsПроизводные индолокарбазолов – перспективный класс противоопухолевых препаратовKiselevaM. P.КиселеваМ. П.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское ш., 24

Марина Петровна Киселева

marina-kiselyova@mail.ruhttps://orcid.org/0000-0003-4006-9320PokrovskyV. S.ПокровскийВ. С.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

6 Miklukho-Maklaya St., Moscow 117198

115478 Москва, Каширское ш., 24

117198 Москва, ул. Миклухо-Маклая, 6

 

TataskiyV. V.ТатарскийВ. В.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское ш., 24

BorisovaL. M.БорисоваЛ. М.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское ш., 24

GolubevaI. S.ГолубеваИ. С.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское ш., 24

EktovaL. V.ЭктоваЛ. В.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское ш., 24

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава РоссииRUDN UniversityРоссийский университет дружбы народов11122018174202609012019090120192018https://bioterapevt.abvpress.ru/jour/article/view/1121

The paper discusses the possible mechanisms of antitumor action of indolocarbazole derivatives. Here we present a data that show interaction drugs based on indolocarbazole derivatives with several intracellular targets and consequently activation different pathways of cell death. Also we present results of our studies on the mechanisms of antitumor action of compounds LCS-1006 and LCS-1208 synthesized in the N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia.

В работе обсуждаются возможные механизмы противоопухолевого действия соединений класса индолокарбазолов. Приводятся литературные данные о способности препаратов на основе производных индолокарбазолов взаимодействовать с несколькими внутриклеточными мишенями и, следовательно, индуцировать разные пути клеточной гибели. Представлены данные по изучению механизма противоопухолевого действия соединений ЛХС-1006 и ЛХС-1208, синтезированных в ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России.

indolocarbazole derivativesmechanism of antitumor actionintracellular targetпроизводные индолокарбазоловмеханизм противоопухолевого действиявнутриклеточные мишени1. Shtil A.A. Signal transduction pathways and transcriptional mechanisms as targets for prevention of emergence of multidrug resistance in human cancer cells (invited review). Current Drug Targets 2001;2:57–77. PMID: 11465539. DOI:10.2174/1389450013348957.Shtil A.A. Signal transduction pathways and transcriptional mechanisms as targets for prevention of emergence of multidrug resistance in human cancer cells (invited review). Current Drug Targets 2001;2:57–77. PMID: 11465539. DOI:10.2174/1389450013348957.2. Блохин Д.Ю., Чмутин Е.Ф., Иванов П.К. Молекулярные мишени для противоопухолевой терапии: факторы роста, ангиогенеза, апоптоза. Российский биотерапевтический журнал 2011;10(3):25–30. [Blokhin D.Y., Chmutin E.F., Ivanov P.K. Molecular targets for anticancer therapy: growth factors, angiogenesis and apoptosis. Rossiyskiy bioterapevticheskiy zhurnal = Russian biotherapeutic journal 2011;10(3):25–30. (In Russ.)].Блохин Д.Ю., Чмутин Е.Ф., Иванов П.К. Молекулярные мишени для противоопухолевой терапии: факторы роста, ангиогенеза, апоптоза. Российский биотерапевтический журнал 2011;10(3):25–30. [Blokhin D.Y., Chmutin E.F., Ivanov P.K. Molecular targets for anticancer therapy: growth factors, angiogenesis and apoptosis. Rossiyskiy bioterapevticheskiy zhurnal = Russian biotherapeutic journal 2011;10(3):25–30. (In Russ.)].3. Блохин Д.Ю., Чмутин Е.Ф., Иванов П.К. Молекулярные мишени для противоопухолевой терапии: пути передачи сигнала и эпигенетические модуляторы. Российский биотерапевтический журнал 2011;10(4):81–8. [Blokhin D.Y., Chmutin E.F., Ivanov P.K. Molecular targets for anticancer therapy: signaling pathways and epigenetic modulators. Rossiyskiy Bioterapevticheskiy zhurnal = Russian Journal of Biotherapy 2011;10(4):81–8. (In Russ.)].Блохин Д.Ю., Чмутин Е.Ф., Иванов П.К. Молекулярные мишени для противоопухолевой терапии: пути передачи сигнала и эпигенетические модуляторы. Российский биотерапевтический журнал 2011;10(4):81–8. [Blokhin D.Y., Chmutin E.F., Ivanov P.K. Molecular targets for anticancer therapy: signaling pathways and epigenetic modulators. Rossiyskiy Bioterapevticheskiy zhurnal = Russian Journal of Biotherapy 2011;10(4):81–8. (In Russ.)].4. Oh Y., Herbst R.S., Burris H. et al. Еnzastaurin, an oral, serine/threonine kinase inhibitor, as second- or third-line therapy of non-small cell lung cancer. J Clin Oncol 2008;26(7):1135–41. PMID: 18309949. DOI: 10.1200/jco.2007.14.3685.Oh Y., Herbst R.S., Burris H. et al. Еnzastaurin, an oral, serine/threonine kinase inhibitor, as second- or third-line therapy of non-small cell lung cancer. J Clin Oncol 2008;26(7):1135–41. PMID: 18309949. DOI: 10.1200/jco.2007.14.3685.5. Rampling R., Sanson M., Gorlia T. et al. A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054). Neuro-Oncology 2012;14:344–50. PMID: 22291006. DOI: 10.1093/neuonc/nor221.Rampling R., Sanson M., Gorlia T. et al. A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054). Neuro-Oncology 2012;14:344–50. PMID: 22291006. DOI: 10.1093/neuonc/nor221.6. OdiaY., Iwamoto F.M., Moustakas A. et al. A phase II trial of enzastaurin (LY317615) in combination with bevacizumab in adults with recurrent malignant gliomas. J Neurooncol 2016;127(1):127–35. PMID: 26643807. +6DOI: 10.1007/s11060-015-2020-x.OdiaY., Iwamoto F.M., Moustakas A. et al. A phase II trial of enzastaurin (LY317615) in combination with bevacizumab in adults with recurrent malignant gliomas. J Neurooncol 2016;127(1):127–35. PMID: 26643807. +6DOI: 10.1007/s11060-015-2020-x.7. Stone R.M., De Angelo D.J., Klimek V. et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molekule FLT3 tyrosine kinase inhibitor, PKC 412. Blood 2005;105:54–60. PMID: 15345597. DOI: 10.1182/blood-2004-03-0891.Stone R.M., De Angelo D.J., Klimek V. et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molekule FLT3 tyrosine kinase inhibitor, PKC 412. Blood 2005;105:54–60. PMID: 15345597. DOI: 10.1182/blood-2004-03-0891.8. Cools J., Mentens N., Furet P. et al. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Res 2004; 64(18): 6385–9. PMID: 15374944. DOI: 10.1158/0008-5472.can-04-2148.Cools J., Mentens N., Furet P. et al. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Res 2004; 64(18): 6385–9. PMID: 15374944. DOI: 10.1158/0008-5472.can-04-2148.9. Колс Ян. Применение Мидостаурина для лечения желудочно-кишечных стромальных опухолей. Патент США № 5093330 от 03.03.1992 г. [Kols Jan (BE) Administration of Midostaurin for treating gastrointeastinal stromal tumours. RU2 410 098 C2. (In Russ.)].Колс Ян. Применение Мидостаурина для лечения желудочно-кишечных стромальных опухолей. Патент США № 5093330 от 03.03.1992 г. [Kols Jan (BE) Administration of Midostaurin for treating gastrointeastinal stromal tumours. RU2 410 098 C2. (In Russ.)].10. Burstein H.J., Overmoyer B., Gelman R. et al. Rebeccamycin analog for refractory breast cancer: a randomized phase II trial of dosing schedules. Invest New Drugs 2007;25(2):161–4. PMID: 16969707. DOI: 10.1007/s10637-006-9007-6.Burstein H.J., Overmoyer B., Gelman R. et al. Rebeccamycin analog for refractory breast cancer: a randomized phase II trial of dosing schedules. Invest New Drugs 2007;25(2):161–4. PMID: 16969707. DOI: 10.1007/s10637-006-9007-6.11. Schwandt A., Mekhail T., Halmos B. et al. Phase-II trial of rebeccamycin analog, a dual topoisomerase-I and -II inhibitor, in relapsed “sensitive” small cell lung cancer. J Thorac Oncol 2012;7(4):751–4. PMID: 22425925. DOI:10.1097/jto.0b013e31824abca2.Schwandt A., Mekhail T., Halmos B. et al. Phase-II trial of rebeccamycin analog, a dual topoisomerase-I and -II inhibitor, in relapsed “sensitive” small cell lung cancer. J Thorac Oncol 2012;7(4):751–4. PMID: 22425925. DOI:10.1097/jto.0b013e31824abca2.12. Goel S., Wadler S., Hoffman A. et al. A phase II study of rebeccamycin analog NSC 655649 in patients with metastatic colorectal cancer. Invest New Drugs 2003;21(1):103–7. PMID: 12795535.Goel S., Wadler S., Hoffman A. et al. A phase II study of rebeccamycin analog NSC 655649 in patients with metastatic colorectal cancer. Invest New Drugs 2003;21(1):103–7. PMID: 12795535.13. Clinical Trials. gov: A service of the U.S. National Institutes of Health. (Accessed on 20 June 2015). [Электронный ресурс]. URL: http://www.clinicaltrials.govClinical Trials. gov: A service of the U.S. National Institutes of Health. (Accessed on 20 June 2015). [Электронный ресурс]. URL: http://www.clinicaltrials.gov14. Sánchez C., Méndez C., Salas J.A. Indolocarbazole natural products: occurrence, biosynthesis, and biological activity. Nat Prod Rep 2006;23:1007–45. PMID: 17119643. DOI: 10.1039/b601930gSánchez C., Méndez C., Salas J.A. Indolocarbazole natural products: occurrence, biosynthesis, and biological activity. Nat Prod Rep 2006;23:1007–45. PMID: 17119643. DOI: 10.1039/b601930g15. Fabbro D., Ruetz S., Buchdunger E. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol Ther 2002;93(2–3):79–98. PMID: 12191602. DOI: 10.1016/S0163-7258(02)00179-1.Fabbro D., Ruetz S., Buchdunger E. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol Ther 2002;93(2–3):79–98. PMID: 12191602. DOI: 10.1016/S0163-7258(02)00179-1.16. Zimmermann A., Wilts H., Lenhardt M. et al. Indolocarbazoles exhibit strong antiviral activity against human cytomegalovirus and are potent inhibitors of the pUL97 protein kinase. Antiviral Res 2000;48:49–60. PMID: 11080540. DOI: 10.1016/S0166-3542(00)00118-2.Zimmermann A., Wilts H., Lenhardt M. et al. Indolocarbazoles exhibit strong antiviral activity against human cytomegalovirus and are potent inhibitors of the pUL97 protein kinase. Antiviral Res 2000;48:49–60. PMID: 11080540. DOI: 10.1016/S0166-3542(00)00118-2.17. Kombarov R., Altieri A., Genis D. et al. BioCores: identification of a drug/natural product-based privileged structural motif for small-molecule lead discovery. Mol divers 2010;14(1):193–200. PMID: 19468851. DOI: 10.1007/s11030-009-9157-5.Kombarov R., Altieri A., Genis D. et al. BioCores: identification of a drug/natural product-based privileged structural motif for small-molecule lead discovery. Mol divers 2010;14(1):193–200. PMID: 19468851. DOI: 10.1007/s11030-009-9157-5.18. Kleinschrot J., Hartenstein J., Rudolf C., Schachtele C. Novel indolocarbazole protein kinase C inhibitors with improved biochemical and physicochemical properties. Bioorg Med Chem Lett 1995;5:55–60.Kleinschrot J., Hartenstein J., Rudolf C., Schachtele C. Novel indolocarbazole protein kinase C inhibitors with improved biochemical and physicochemical properties. Bioorg Med Chem Lett 1995;5:55–60.19. Goekjian P.G., Jirousek M.R. Protein kinase С in the treatment of disease: signal transduction pathways, inhibitors, and agents in development. Curr Med Chem 1999;6:877–903. PMID: 10495357.Goekjian P.G., Jirousek M.R. Protein kinase С in the treatment of disease: signal transduction pathways, inhibitors, and agents in development. Curr Med Chem 1999;6:877–903. PMID: 10495357.20. Bridges A.J. Chemical Inhibitors of Protein Kinases. Chem Rev 2001; 101:2541–71. DOI: 10.1021/cr000250y.Bridges A.J. Chemical Inhibitors of Protein Kinases. Chem Rev 2001; 101:2541–71. DOI: 10.1021/cr000250y.21. Bush J.A., Long В.H., Catino J.J., Bradner W.T. Production and biological activity of rebeccamycin, a novel antitumor agent. J Antibiotics 1987;40:668–78. PMID: 3112080. DOI: 10.7164/antibiotics.40.668.Bush J.A., Long В.H., Catino J.J., Bradner W.T. Production and biological activity of rebeccamycin, a novel antitumor agent. J Antibiotics 1987;40:668–78. PMID: 3112080. DOI: 10.7164/antibiotics.40.668.22. Sordet O., Khan Q.A., Kohn K.W., Pommier Y. Apoptosis induced by topoisomerase inhibitors. Curr. Med. Chem. Anticancer Agents 2003;3(4):271–90. DOI: 10.2174/1568011033482378.Sordet O., Khan Q.A., Kohn K.W., Pommier Y. Apoptosis induced by topoisomerase inhibitors. Curr. Med. Chem. Anticancer Agents 2003;3(4):271–90. DOI: 10.2174/1568011033482378.23. Смирнова З.С., Борисова Л.М., Киселева М.П. и др. Поиск ингибиторов топоизомераз I и/или II среди N-гликозидов производных индоло-[2,3-а]карбазолов для лечения злокачественных опухолей. Материалы симпозиума «Результаты фундаментальных и прикладных исследований для создания новых лекарственных средств»(Москва, 9–11 июня 2008 г.). М.: Фирма «Слово», 2008. С. 191–92. [Smirnova Z.S., Borisova L.M., Kiseleva M.P. et al. Search for inhibitors of topoisomerases I and/or II among n-glycosides of indolo derivatives [2,3-a] carbazoles for the treatment of malignant tumors. Materials of the Symposium “results of fundamental and applied research for the development of new drugs” (Moscow, June 9–11, 2008). M.: Company “Word”, 2008. P. 191–92. (In Russ.)].Смирнова З.С., Борисова Л.М., Киселева М.П. и др. Поиск ингибиторов топоизомераз I и/или II среди N-гликозидов производных индоло-[2,3-а]карбазолов для лечения злокачественных опухолей. Материалы симпозиума «Результаты фундаментальных и прикладных исследований для создания новых лекарственных средств»(Москва, 9–11 июня 2008 г.). М.: Фирма «Слово», 2008. С. 191–92. [Smirnova Z.S., Borisova L.M., Kiseleva M.P. et al. Search for inhibitors of topoisomerases I and/or II among n-glycosides of indolo derivatives [2,3-a] carbazoles for the treatment of malignant tumors. Materials of the Symposium “results of fundamental and applied research for the development of new drugs” (Moscow, June 9–11, 2008). M.: Company “Word”, 2008. P. 191–92. (In Russ.)].24. List A.F. Non-P-glycoprotein drug export mechanisms of multidrug resistance. Semin Hematol 1997; 34(4 Suppl 5):40–7. PMID: 9408957.List A.F. Non-P-glycoprotein drug export mechanisms of multidrug resistance. Semin Hematol 1997; 34(4 Suppl 5):40–7. PMID: 9408957.25. Gescher A. Analogs of staurosporine: potential anticancer drugs. Biochem Pharmacol 1998;31:721–28. PMID: 9809468.Gescher A. Analogs of staurosporine: potential anticancer drugs. Biochem Pharmacol 1998;31:721–28. PMID: 9809468.26. Akinaga S., Gomi K., Morimoto M. et al. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res 1991;51:4888–92. PMID: 1893379.Akinaga S., Gomi K., Morimoto M. et al. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res 1991;51:4888–92. PMID: 1893379.27. Sikic B.I. Pharmacologic approaches to reversing multidrug resistance. Semin Hematol 1997;34(4 Suppl 5):40–7. PMID: 9408960.Sikic B.I. Pharmacologic approaches to reversing multidrug resistance. Semin Hematol 1997;34(4 Suppl 5):40–7. PMID: 9408960.28. Xia P., Aiello L.P., Ishii H. et al. Characterization of vascular endothelial growth factor’s effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 1996;98:2018–26. PMID: 8903320. DOI: 10.1172/JCl119006.Xia P., Aiello L.P., Ishii H. et al. Characterization of vascular endothelial growth factor’s effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 1996;98:2018–26. PMID: 8903320. DOI: 10.1172/JCl119006.29. Ruggeri B., Singh J., Gingrich D. et al. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Cancer Res 2003;63(18):5978–91. PMID: 14522925.Ruggeri B., Singh J., Gingrich D. et al. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Cancer Res 2003;63(18):5978–91. PMID: 14522925.30. Bredel M., Pollack I.F., Freund J.M. et al. Protein kinase C inhibition by UCN-01 induces apoptosis in human glioma cells in a time-dependent fashion. J Neurooncol 1999;41:9–20. PMID: 10222418.Bredel M., Pollack I.F., Freund J.M. et al. Protein kinase C inhibition by UCN-01 induces apoptosis in human glioma cells in a time-dependent fashion. J Neurooncol 1999;41:9–20. PMID: 10222418.31. Rosnet O., Buhring H.J., Marchetto S. et al. Human FLT3/FLK2 receptor tyrosine kinaseis expressed at the surface of normal and malignant hematopoietic cells. Leukemia 1996;10:248. PMID: 8637232.Rosnet O., Buhring H.J., Marchetto S. et al. Human FLT3/FLK2 receptor tyrosine kinaseis expressed at the surface of normal and malignant hematopoietic cells. Leukemia 1996;10:248. PMID: 8637232.32. Weiseberg E., Boulton C., Kelly L.M. et al. Inhibiton of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC. Int J Cancer 2002;1(5):433–43. PMID: 12124173. DOI:10.1016/s1535-6108(02)00069-7.Weiseberg E., Boulton C., Kelly L.M. et al. Inhibiton of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC. Int J Cancer 2002;1(5):433–43. PMID: 12124173. DOI:10.1016/s1535-6108(02)00069-7.33. Faul M.M., Gillig J.R., Jirousek M.R. et al. Acyclic N-(azacycloalkyl) bisindolylmaleimides: isozyme selective inhibitors of PKCβ. Bioorg Med Chem Lett 2003;13:1857–9. PMID: 12749884. DOI:10.1002/chin.200336180.Faul M.M., Gillig J.R., Jirousek M.R. et al. Acyclic N-(azacycloalkyl) bisindolylmaleimides: isozyme selective inhibitors of PKCβ. Bioorg Med Chem Lett 2003;13:1857–9. PMID: 12749884. DOI:10.1002/chin.200336180.34. Querfeld C., Rizvi M.A., Kuzel T.M. et al. The selective protein kinase Cβ inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J Invest Dermatol 2006;126(7):1641–7. PMID: 16645590. DOI: 10.1038/sj.jid.5700322.Querfeld C., Rizvi M.A., Kuzel T.M. et al. The selective protein kinase Cβ inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J Invest Dermatol 2006;126(7):1641–7. PMID: 16645590. DOI: 10.1038/sj.jid.5700322.35. Rizvi M.A., Ghias K., Davies K.M. et al. Enzastaurin(LY317615), a protein kinase Cβ inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Mol Cancer Ther 2006;5:1783–9. PMID: 16891464. DOI: 10.1158/1535-7163.MCT-05-0465.Rizvi M.A., Ghias K., Davies K.M. et al. Enzastaurin(LY317615), a protein kinase Cβ inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Mol Cancer Ther 2006;5:1783–9. PMID: 16891464. DOI: 10.1158/1535-7163.MCT-05-0465.36. Denny W.A. Emerging DNA topoisomerase inhibitors as anticancer drugs. Expert Opin Emerg Drugs 2004;9:105–33. DOI: 10.1517/14728214.9.1.105.Denny W.A. Emerging DNA topoisomerase inhibitors as anticancer drugs. Expert Opin Emerg Drugs 2004;9:105–33. DOI: 10.1517/14728214.9.1.105.37. Long B.H., Rose W.S., Vyas D.M. et al. Discoveri of antitumor indolocarbazoles: Rebeccamycin, NSC 655649, and fluoroloindolocarbazoles. Curr Med Chem Anticancer Agents 2002;2:255–66. PMID: 12678746. DOI: 10.2174/1568011023354218.Long B.H., Rose W.S., Vyas D.M. et al. Discoveri of antitumor indolocarbazoles: Rebeccamycin, NSC 655649, and fluoroloindolocarbazoles. Curr Med Chem Anticancer Agents 2002;2:255–66. PMID: 12678746. DOI: 10.2174/1568011023354218.38. Yoshinari T., Ohkubo M., Fukasawa K. et al. Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I. Cancer Res 1999;59:4271–5. PMID: 10485471.Yoshinari T., Ohkubo M., Fukasawa K. et al. Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I. Cancer Res 1999;59:4271–5. PMID: 10485471.39. Yoshinari T., Yamada A., Uemura D. et al. Induction of Topoisomerase I-mediated DNA Cleavage by a New Indolocarbazole, ED-110. Cancer Res 1993;53:490–4. PMID: 8381047.Yoshinari T., Yamada A., Uemura D. et al. Induction of Topoisomerase I-mediated DNA Cleavage by a New Indolocarbazole, ED-110. Cancer Res 1993;53:490–4. PMID: 8381047.40. Ohkubo M., Kojiri K., Kondo H. et al. Synthesis and Biological Activities of Topoisomerase I Inhibitors, 6-N-amino analogues of NB-506. Bioorg Med Chem Letters 1999;9:1219–24. PMID: 10340602.Ohkubo M., Kojiri K., Kondo H. et al. Synthesis and Biological Activities of Topoisomerase I Inhibitors, 6-N-amino analogues of NB-506. Bioorg Med Chem Letters 1999;9:1219–24. PMID: 10340602.41. Sherer C., Snape T.J. Heterocyclic scaffolds as promising anticancer agents against tumours of the central nervous system: Exploring the scope of indole and carbazole derivatives. Eur J Med Chem 2015;97:552–60. PMID: 25466446. DOI: 10.1016/j.ejmech.2014.11.007.Sherer C., Snape T.J. Heterocyclic scaffolds as promising anticancer agents against tumours of the central nervous system: Exploring the scope of indole and carbazole derivatives. Eur J Med Chem 2015;97:552–60. PMID: 25466446. DOI: 10.1016/j.ejmech.2014.11.007.42. Смирнова З.С., Кубасова И.Ю., Борисова Л.М. и др. Изучение противоопухолевой активности производного индоло[2,3-a]карбазола ЛХС-1006. Российский биотерапевтический журнал 2005;4(1):70–1. [Smirnova Z.S., Kubasova I.Yu., Borisova L.M. et al. The study of the antitumor activity of the indolo[2,3-a] carbazole derivative LHS-1006. Rossiysky Biotherapevtichesky Zhurnal = Russian Journal of Biotherapy 2005;4(1):70–1. (In Russ.)].Смирнова З.С., Кубасова И.Ю., Борисова Л.М. и др. Изучение противоопухолевой активности производного индоло[2,3-a]карбазола ЛХС-1006. Российский биотерапевтический журнал 2005;4(1):70–1. [Smirnova Z.S., Kubasova I.Yu., Borisova L.M. et al. The study of the antitumor activity of the indolo[2,3-a] carbazole derivative LHS-1006. Rossiysky Biotherapevtichesky Zhurnal = Russian Journal of Biotherapy 2005;4(1):70–1. (In Russ.)].43. Татарский В.В. Механизмы гибели опухолевых клеток при действии новых углеводных производных индолокарбазолов. Автореф. дис. … канд. биол. наук. Москва, 2 сентября 2010. 22 с. [Tatarsky V.V. Mechanisms of tumor cell death under the action of new carbohydrate derivatives of indolocarbazoles. Abstract. Dis …. kand. biol. sciences. Moscow, September 2, 2010. 22 р. (In Russ.)].Татарский В.В. Механизмы гибели опухолевых клеток при действии новых углеводных производных индолокарбазолов. Автореф. дис. … канд. биол. наук. Москва, 2 сентября 2010. 22 с. [Tatarsky V.V. Mechanisms of tumor cell death under the action of new carbohydrate derivatives of indolocarbazoles. Abstract. Dis …. kand. biol. sciences. Moscow, September 2, 2010. 22 р. (In Russ.)].44. Киселева М.П., Шпрах З.С., Деженкова Л.Г. и др. Действие производного индолокарбазолов ЛХС-1208 на топоизомеразу I. Российский биотерапевтический журнал 2015;14(1):89. [Kiseleva M.P., Shprakh Z.S., Dezhenkova L.G. et al. Effect of indocarbazole derivative LHS-1208 on topoisomerase I. Rossiysky Biotherapevtichesky Zhurnal = Russian Journal of Biotherapy 2015;14(1):89. (In Russ.)].Киселева М.П., Шпрах З.С., Деженкова Л.Г. и др. Действие производного индолокарбазолов ЛХС-1208 на топоизомеразу I. Российский биотерапевтический журнал 2015;14(1):89. [Kiseleva M.P., Shprakh Z.S., Dezhenkova L.G. et al. Effect of indocarbazole derivative LHS-1208 on topoisomerase I. Rossiysky Biotherapevtichesky Zhurnal = Russian Journal of Biotherapy 2015;14(1):89. (In Russ.)].45. Киселева М.П., Шпрах З.С., Борисова Л.М. и др. Доклиническое изучение противоопухолевой активности производного N-гликозида индолокарбазола ЛХС-1208. Сообщение II. Российский биотерапевтический журнал 2015;3:41–8. [Kiseleva M.P., Shprakh Z.S., Borisova L.M. et al. Preclinical study of antitumor activity of indolocarbasoles N-glycosides derivative LCS-1208. Report II. Rossiysky Biotherapevtichesky Zhurnal = Russian Journal of Biotherapy 2015;3:41–8. (In Russ.)].Киселева М.П., Шпрах З.С., Борисова Л.М. и др. Доклиническое изучение противоопухолевой активности производного N-гликозида индолокарбазола ЛХС-1208. Сообщение II. Российский биотерапевтический журнал 2015;3:41–8. [Kiseleva M.P., Shprakh Z.S., Borisova L.M. et al. Preclinical study of antitumor activity of indolocarbasoles N-glycosides derivative LCS-1208. Report II. Rossiysky Biotherapevtichesky Zhurnal = Russian Journal of Biotherapy 2015;3:41–8. (In Russ.)].46. Kaluzhny D.N., Tatarskiy V.V., Dezhenkova L.G. et al. Novel antitumor L-arabinose derivative of indolocarbazole with high affinity to DNA. Chem Med Chem 2009;4(10):1641–8. PMID: 19672918. DOI:10.1002/cmdc.200900227.Kaluzhny D.N., Tatarskiy V.V., Dezhenkova L.G. et al. Novel antitumor L-arabinose derivative of indolocarbazole with high affinity to DNA. Chem Med Chem 2009;4(10):1641–8. PMID: 19672918. DOI:10.1002/cmdc.200900227.47. Tatarskiy V.V., Kaluzhny D.N., Shchyolkina A.K. et al. High antitumor activity of novel glycosylated indolocarbazole is determined by strong intercalation into DNA. Proc. 14th Euroconference on Apoptosis “Death or Survival: Fate in Sardinia”, Chia, Italy, 2006 230 р.Tatarskiy V.V., Kaluzhny D.N., Shchyolkina A.K. et al. High antitumor activity of novel glycosylated indolocarbazole is determined by strong intercalation into DNA. Proc. 14th Euroconference on Apoptosis “Death or Survival: Fate in Sardinia”, Chia, Italy, 2006 230 р.48. Denny W.A. Emerging DNA topoisomerase inhibitors as anticancer drugs. Expert Opin Emerg Drugs 2004;9:105–33. PMID: 15155139. DOI:10.1517/14728214.9.1.105.Denny W.A. Emerging DNA topoisomerase inhibitors as anticancer drugs. Expert Opin Emerg Drugs 2004;9:105–33. PMID: 15155139. DOI:10.1517/14728214.9.1.105.49. Jackson J.R., Gilmartin A., Imburgia C. et al. An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage. Cancer Res 2000;60:566–72. PMID: 10676638.Jackson J.R., Gilmartin A., Imburgia C. et al. An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage. Cancer Res 2000;60:566–72. PMID: 10676638.50. Kaluzhny D.N., Borisova O.F., Shchyolkina A.K. et al. Novel antitumor L-arabinose derivative of indolocarbazole with high affinity to the duplex and telomeric G-quadruplex DNA. Second International Meeting on Quadruplex DNA, Louisville, KY, 2009 60 р.Kaluzhny D.N., Borisova O.F., Shchyolkina A.K. et al. Novel antitumor L-arabinose derivative of indolocarbazole with high affinity to the duplex and telomeric G-quadruplex DNA. Second International Meeting on Quadruplex DNA, Louisville, KY, 2009 60 р.51. Калюжный Д.Н., Татарский В.В., Бондарев Ф.С. и др. Взаимодействие с ДНК как фактор цитотоксичности нового гликозидного производного индолокарбазола. Доклады РАН. 2006;411(6):833–836. [Kaluzhny D.N., Tatarskiyjr V.V., Bondarev F.S. et al. Interaction with DNA as a Factor of Cytotoxicity of Novel Glycosylated Derivative of Indocarbazole. Reports of RAS. 2006;411(6):833–36. (In Russ.)].Калюжный Д.Н., Татарский В.В., Бондарев Ф.С. и др. Взаимодействие с ДНК как фактор цитотоксичности нового гликозидного производного индолокарбазола. Доклады РАН. 2006;411(6):833–836. [Kaluzhny D.N., Tatarskiyjr V.V., Bondarev F.S. et al. Interaction with DNA as a Factor of Cytotoxicity of Novel Glycosylated Derivative of Indocarbazole. Reports of RAS. 2006;411(6):833–36. (In Russ.)].52. Татарский В.В., Плихтяк И.Л., Мельник С.Я. и др. Механизмы противоопухолевого действия нового производного индолокарбазолов. Материалы конференции «Фундаментальная онкология. 2-е Чтения им. проф. Н.Н. Петрова». Санкт-Петербург, 2006. Вопросы онкологии 2006;52:38–9. [Tatarskiy V.V., Plikhtyak I.L., Mel’nik S.Ya. et al. Mechanisms of the antitumor action of a new derivative of indolocarbazoles. Proceedings of the conference “Fundamental Oncology. 2nd Readings to them. prof. N.N. Petrov. St. Petersburg. Voprosy oncologiy = Oncology issues 2006;52:38–9. (In Russ.)].Татарский В.В., Плихтяк И.Л., Мельник С.Я. и др. Механизмы противоопухолевого действия нового производного индолокарбазолов. Материалы конференции «Фундаментальная онкология. 2-е Чтения им. проф. Н.Н. Петрова». Санкт-Петербург, 2006. Вопросы онкологии 2006;52:38–9. [Tatarskiy V.V., Plikhtyak I.L., Mel’nik S.Ya. et al. Mechanisms of the antitumor action of a new derivative of indolocarbazoles. Proceedings of the conference “Fundamental Oncology. 2nd Readings to them. prof. N.N. Petrov. St. Petersburg. Voprosy oncologiy = Oncology issues 2006;52:38–9. (In Russ.)].